Mapping Brain Regions in Which Deep Brain Stimulation Affects Schizophrenia-Like Behavior in Two Rat Models of Schizophrenia

Abstract Background and Objectives The development of more efficient treatment remains a major unmet need in the realm of schizophrenia disease. Using the maternal immune stimulation and the pubertal cannabinoid administration rat model of schizophrenia, the present study aimed at testing the hypothesis that deep brain stimulation (DBS) serves as a novel therapeutic technique for this disorder. Methods Adult offspring of dams, treated with the immune activating agent poly I:C (4 mg/kg, n  = 50) or saline ( n  = 50), underwent bilateral stereotactic electrode implantation into one of the following brain regions: subthalamic nucleus (STN, n  = 12/10), entopeduncularis nucleus (EP, n  = 10/11), globus pallidus (GP, n  = 10/10), medial prefrontal cortex (mPFC, n  = 8/8), or dorsomedial thalamus (DM, n  = 10/11). Adult rats treated with the CB1 receptor agonist WIN 55,212-2 (WIN, n  = 16) or saline ( n  = 12) during puberty were bilaterally implanted with electrodes into either the mPFC ( n  = 8/6) or the DM ( n  = 8/6). After a post-operative recovery period of one week, all rats were tested on a well-established cross-species phenomenon that is disrupted in schizophrenia, the pre-pulse inhibition (PPI) of the acoustic startle reflex (ASR) under different DBS conditions. Results Poly I:C induced deficits in PPI of the ASR were normalized upon DBS. DBS effects depended on both stimulation target and stimulation parameters. Most prominent effects were found under DBS at high frequencies in the mPFC and DM. These effects were replicated in the pubertal WIN administration rat model of schizophrenia. Conclusions Brain regions, in which DBS normalized PPI deficits, might be of therapeutic relevance to the treatment of schizophrenia. Results imply that DBS could be considered a plausible therapeutic technique in the realm of schizophrenia disease.